Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth.
Humans
Glioblastoma
/ genetics
Vascular Endothelial Growth Factor A
/ genetics
Phosphorylation
beta Catenin
/ genetics
Proto-Oncogene Proteins c-akt
/ metabolism
Phosphofructokinase-1
/ metabolism
Vascular Endothelial Growth Factors
/ metabolism
Brain Neoplasms
/ genetics
Protein Isoforms
/ metabolism
ErbB Receptors
/ metabolism
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
26 11 2022
26 11 2022
Historique:
received:
22
06
2022
accepted:
16
11
2022
revised:
14
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
entrez:
26
11
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is a highly vascular malignant brain tumor that overexpresses vascular endothelial growth factor (VEGF) and phosphofructokinase 1 platelet isoform (PFKP), which catalyzes a rate-limiting reaction in glycolysis. However, whether PFKP and VEGF are reciprocally regulated during GBM tumor growth remains unknown. Here, we show that PFKP can promote EGFR activation-induced VEGF expression in HIF-1α-dependent and -independent manners in GBM cells. Importantly, we demonstrate that EGFR-phosphorylated PFKP Y64 has critical roles in both AKT/SP1-mediated transcriptional expression of HIF-1α and in the AKT-mediated β-catenin S552 phosphorylation, to fully enhance VEGF transcription, subsequently promoting blood vessel formation and brain tumor growth. Levels of PFKP Y64 phosphorylation in human GBM specimens are positively correlated with HIF-1α expression, β-catenin S552 phosphorylation, and VEGF expression. Conversely, VEGF upregulates PFKP expression in a PFKP S386 phosphorylation-dependent manner, leading to increased PFK enzyme activity, aerobic glycolysis, and proliferation in GBM cells. These findings highlight a novel mechanism underlying the mutual regulation that occurs between PFKP and VEGF for promoting GBM tumor growth and also suggest that targeting the PFKP/VEGF regulatory loop might show therapeutic potential for treating GBM patients.
Identifiants
pubmed: 36435833
doi: 10.1038/s41419-022-05449-6
pii: 10.1038/s41419-022-05449-6
pmc: PMC9701207
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
beta Catenin
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Phosphofructokinase-1
EC 2.7.1.11
Vascular Endothelial Growth Factors
0
Protein Isoforms
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1002Informations de copyright
© 2022. The Author(s).
Références
Methods Mol Biol. 2016;1516:361-369
pubmed: 27044042
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Neoplasia. 2007 May;9(5):406-17
pubmed: 17534446
Mol Cell Biol. 2009 May;29(10):2483-8
pubmed: 19273606
J Biol Chem. 2002 Dec 13;277(50):48403-9
pubmed: 12379645
Genomics. 1998 Sep 1;52(2):159-65
pubmed: 9782081
Cancer Res. 2000 Oct 15;60(20):5879-86
pubmed: 11059786
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Nature. 1992 Oct 29;359(6398):843-5
pubmed: 1279431
Mol Cell Biol. 1996 Sep;16(9):4604-13
pubmed: 8756616
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
Mol Cancer Res. 2014 Aug;12(8):1100-11
pubmed: 24759089
Cold Spring Harb Symp Quant Biol. 2011;76:211-6
pubmed: 22096029
J Cell Physiol. 2013 Feb;228(2):341-8
pubmed: 22718198
J Cell Sci. 2003 Jan 15;116(Pt 2):225-38
pubmed: 12482909
Cell. 2010 Jan 22;140(2):268-79
pubmed: 20141840
J Biol Chem. 2005 Jun 10;280(23):22473-81
pubmed: 15802268
EMBO Rep. 2017 Jan;18(1):150-168
pubmed: 27993939
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32860047
Blood. 2001 Sep 15;98(6):1904-13
pubmed: 11535528
Front Oncol. 2020 Mar 05;10:211
pubmed: 32195176
Nat Commun. 2017 Oct 16;8(1):949
pubmed: 29038421
Mol Cell. 2018 Apr 19;70(2):197-210.e7
pubmed: 29677490
Oncotarget. 2017 Oct 10;8(61):103657-103670
pubmed: 29262591
J Clin Oncol. 2013 Sep 10;31(26):3212-8
pubmed: 23940216
Mol Cell Biol. 2001 Jun;21(12):3995-4004
pubmed: 11359907
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Cell Cycle. 2007 Feb 15;6(4):467-70
pubmed: 17312396
Nature. 1994 Feb 10;367(6463):576-9
pubmed: 8107827
Cancer Res. 2011 Feb 15;71(4):1474-85
pubmed: 21212411
PLoS Biol. 2015 May 20;13(5):e1002152
pubmed: 25992628
Nat Rev Mol Cell Biol. 2011 Feb;12(2):104-17
pubmed: 21252999
Cell Metab. 2021 Jan 5;33(1):33-50
pubmed: 33406403
Int J Cancer. 1999 Feb 19;84(1):10-8
pubmed: 9988225
J Androl. 2001 May-Jun;22(3):432-43
pubmed: 11330643
Mol Biol Cell. 2004 Nov;15(11):4841-53
pubmed: 15342781
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Acta Neuropathol. 2015 Jan;129(1):115-31
pubmed: 25322816
Onco Targets Ther. 2014 Sep 05;7:1551-62
pubmed: 25228814
Curr Opin Genet Dev. 1998 Oct;8(5):588-94
pubmed: 9794818
Cancer Res. 1995 Mar 1;55(5):1189-93
pubmed: 7532545
FEBS J. 2007 Mar;274(6):1393-418
pubmed: 17302740
Nat Rev Neurosci. 2007 Aug;8(8):610-22
pubmed: 17643088
Int J Cancer. 2006 Oct 1;119(7):1519-29
pubmed: 16671089
Oncol Lett. 2016 Dec;12(6):4598-4604
pubmed: 28101216
Int J Cancer. 1999 Mar 31;81(1):118-24
pubmed: 10077162
Cancer Res. 2003 Jun 15;63(12):3145-53
pubmed: 12810642
Cell Cycle. 2008 Aug 15;7(16):2553-61
pubmed: 18719373
J Biol Chem. 2007 Apr 13;282(15):11221-9
pubmed: 17287208
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
Nature. 2006 May 25;441(7092):437-43
pubmed: 16724055